Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Conduit Pharmaceuticals Inc.

US CDTTW

0.015USD
0.0064(74.42%)

Last update at 2026-06-03T19:43:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0050.02
LowHigh

Fundamentals

  • Previous Close 0.0086
  • Market Cap0.00000M
  • Volume2821
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-34.33200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 266.87M -17.80200M 2.84M -4.88700M -3.65700M
Minority interest - - - - -
Net income 237.52M -17.80200M -0.53500M -4.88700M -3.65700M
Selling general administrative 533.37M 12.04M 5.17M 3.05M 2.89M
Selling and marketing expenses - - - - -
Gross profit 1031.17M -0.45700M - - -
Reconciled depreciation 2.42M 0.46M 0.00000M - -
Ebit 318.16M -16.29600M -0.32400M -3.16000M -3.17300M
Ebitda 371.52M -15.83900M 3.05M -1.43300M -2.68900M
Depreciation and amortization 53.36M 0.46M 0.17M 1.73M 0.48M
Non operating income net other - - - - -
Operating income 315.69M -15.41900M -5.26200M -3.16000M -3.17300M
Other operating expenses 2399.50M 15.42M 5.26M 3.16M 3.17M
Interest expense 46.35M 1.51M 0.21M - -
Tax provision - - - - -
Interest income 0.03M 0.01M 0.03M - -
Net interest income -0.29100M -1.49300M -0.39200M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 29.34M -29.52800M -0.16800M - -
Total revenue 2715.19M 922.22M 0.00000M 0.00000M 0.00000M
Total operating expenses 715.48M 14.96M 5.26M 3.16M 3.17M
Cost of revenue 1684.02M 0.46M - - -
Total other income expense net -48.82600M -2.38300M 8.10M -1.72700M -0.48400M
Discontinued operations - - - - -
Net income from continuing ops -39.22400M -17.81200M -0.53500M -4.88700M -3.65700M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3543.62M 4.19M 7.22M 0.00500M 0.00000M
Intangible assets 399.80M 419.07M - 0.00500M -
Earning assets - - - - -
Other current assets 94.30M 1.67M 1.50M - -
Total liab 2279.20M 10.99M 7.68M 10.08M 5.94M
Total stockholder equity 1264.42M -6.79300M -0.45700M -10.07600M -5.94200M
Deferred long term liab - - - - -
Other current liab 336.07M 1.96M 0.60M 3.99M 2.23M
Common stock 0.50M 0.01M 0.00700M - -
Capital stock 0.00000M 0.01M 0.00700M 0.00000M 0.00000M
Retained earnings 1405.57M -29.10100M -11.29900M -10.76400M -5.87700M
Other liab - - - - -
Good will 1036.82M 1018.68M - - -
Other assets - - - - -
Cash 389.89M 0.55M 4.23M - -
Cash and equivalents - - - - -
Total current liabilities 697.50M 10.74M 1.80M 3.99M 2.23M
Current deferred revenue - - - - -
Net debt 895.78M 6.90M -3.24300M 2.01M 0.75M
Short term debt - 7.35M 0.98M - -
Short long term debt 0.66M 7.23M 0.98M - -
Short long term debt total 1285.67M 7.46M 0.98M 2.01M 0.75M
Other stockholder equity -44.44700M 21.88M 10.42M - -
Property plant equipment - - - - -
Total current assets 1349.38M 2.71M 5.73M - -
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - 369.75M - - -
Net receivables 462.85M 0.49M - - -
Long term debt - - - 2.01M 0.75M
Inventory 402.35M 343.10M - - -
Accounts payable 361.43M 1.43M 0.21M - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -97.20400M 0.41M 0.41M 0.69M -0.06500M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 177.09M -1436.57600M 1.49M - -
Deferred long term asset charges - - - - -
Non current assets total 2194.24M 1.48M 1.49M 0.00500M 0.00000M
Capital lease obligations 0.12M 0.23M - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -0.04300M 0.72M -0.18300M 0.00000M
Change to liabilities - - - - -
Total cashflows from investing activities -128.23700M -0.04300M 0.72M - -
Net borrowings -2.17100M 2.45M 2.29M - -
Total cash from financing activities -217.77200M 6.07M 10.93M 2.45M 1.90M
Change to operating activities - - - - -
Net income 237.52M -17.80200M -0.53500M -4.88700M -3.65700M
Change in cash 19.59M -3.67400M 4.23M 0.00000M -0.25200M
Begin period cash flow 370.30M 4.23M 0.35M 0.00000M 0.25M
End period cash flow 389.89M 0.55M 4.23M 0.00000M 0.00000M
Total cash from operating activities 354.86M -9.68200M -7.72500M -2.26600M -2.15100M
Issuance of capital stock 19.70M 3.33M 0.00000M 1.34M 1.21M
Depreciation 129.43M 0.46M 0.00000M - -
Other cashflows from investing activities 0.19M -0.71300M 0.23M - -
Dividends paid 7.97M 8.20M - - -
Change to inventory -48.23200M 24.32M - - -
Change to account receivables -37.77100M 18.86M - - -
Sale purchase of stock -0.10600M 0.00000M - - -
Other cashflows from financing activities -227.22800M 0.29M 8.64M 1.11M 0.69M
Change to netincome - - - - -
Capital expenditures 136.17M 0.05M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.73M -0.14200M -2.51600M 0.93M 1.36M
Stock based compensation 30.02M 1.63M 0.20M - -
Other non cash items -51.86200M 6.17M -4.87300M 1.69M 0.15M
Free cash flow 218.69M -9.73300M -7.72500M -2.26600M -2.15100M

Peer Comparison

Sector: Industry:

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CDTTW
Conduit Pharmaceuticals Inc.		 0.0064 74.42% 0.01 - - - -
DOGEF
Orsted A/S		 - -% 26.19 28.82 0.66 6.50 0.07 3.88 15.58
NCRRP
NCR Corp Pref A		 - -% 1002.00 1034.35 - - -
TBB
AT&T Inc. 5.35% GLB NTS 66		 -0.21 1.00% 20.76 4.60 - - -
CCZ
Comcast Holdings Corp		 2.39 3.82% 64.94 55.07 - - -

Reports Covered

Stock Research & News

View All

Profile

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Conduit Pharmaceuticals Inc.

4581 Tamiami Trail North, Naples, FL, United States, 34103

Key Executives

Name Title Year Born
Dr. David Joszef Tapolczay CEO & Director 1959
Mr. Adam Sragovicz Chief Financial Officer 1970
Dr. Joanne M. Holland Chief Scientific Officer 1975
Mr. James Bligh Interim CFO & Director 1988
Mr. Bill Begien Senior VP of Investor Relations NA
Dr. Andrew Regan Founder, CEO & Director 1967
Mr. James Bligh Co-Founder, CFO & Director 1988

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.